Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Mutations in NONO lead to syndromic intellectual disability and inhibitory synaptic defects


The NONO protein has been characterized as an important transcriptional regulator in diverse cellular contexts. Here we show that loss of NONO function is a likely cause of human intellectual disability and that NONO-deficient mice have cognitive and affective deficits. Correspondingly, we find specific defects at inhibitory synapses, where NONO regulates synaptic transcription and gephyrin scaffold structure. Our data identify NONO as a possible neurodevelopmental disease gene and highlight the key role of the DBHS protein family in functional organization of GABAergic synapses.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: NONO mutations and their functional consequences.
Figure 2: Transcriptome analysis in human and mouse cells.
Figure 3: Functional consequences of NONO deficiency in mice.
Figure 4: Effects of NONO deficiency on synaptic biology.
Figure 5: GABA receptor overexpression rescues synaptic structural defects.

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

Referenced accessions

NCBI Reference Sequence


  1. Fox, A.H., Bond, C.S. & Lamond, A.I. P54nrb forms a heterodimer with PSP1 that localizes to paraspeckles in an RNA-dependent manner. Mol. Biol. Cell 16, 5304–5315 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Myojin, R. et al. Expression and functional significance of mouse paraspeckle protein 1 on spermatogenesis. Biol. Reprod. 71, 926–932 (2004).

    Article  CAS  PubMed  Google Scholar 

  3. Shav-Tal, Y. & Zipori, D. PSF and p54nrb/NonO – multi-functional nuclear proteins. FEBS Lett. 531, 109–114 (2002).

    Article  CAS  PubMed  Google Scholar 

  4. Dong, X., Sweet, J., Challis, J.R., Brown, T. & Lye, S.J. Transcriptional activity of androgen receptor is modulated by two RNA splicing factors, PSF and p54nrb. Mol. Cell. Biol. 27, 4863–4875 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Amelio, A.L. et al. A coactivator trap identifies NONO (p54nrb) as a component of the cAMP-signaling pathway. Proc. Natl. Acad. Sci. USA 104, 20314–20319 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Park, Y., Lee, J.M., Hwang, M.Y., Son, G.H. & Geum, D. NonO binds to the CpG island of oct4 promoter and functions as a transcriptional activator of oct4 gene expression. Mol. Cells 35, 61–69 (2013).

    Article  CAS  PubMed  Google Scholar 

  7. Kim, K.K., Kim, Y.C., Adelstein, R.S. & Kawamoto, S. Fox-3 and PSF interact to activate neural cell-specific alternative splicing. Nucleic Acids Res. 39, 3064–3078 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Patton, J.G., Porro, E.B., Galceran, J., Tempst, P. & Nadal-Ginard, B. Cloning and characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev. 7, 393–406 (1993).

    Article  CAS  PubMed  Google Scholar 

  9. Kaneko, S., Rozenblatt-Rosen, O., Meyerson, M. & Manley, J.L. The multifunctional protein p54nrb/PSF recruits the exonuclease XRN2 to facilitate pre-mRNA 3′ processing and transcription termination. Genes Dev. 21, 1779–1789 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kanai, Y., Dohmae, N. & Hirokawa, N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron 43, 513–525 (2004).

    Article  CAS  PubMed  Google Scholar 

  11. Izumi, H., McCloskey, A., Shinmyozu, K. & Ohno, M. p54nrb/NonO and PSF promote U snRNA nuclear export by accelerating its export complex assembly. Nucleic Acids Res. 42, 3998–4007 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nakagawa, S. & Hirose, T. Paraspeckle nuclear bodies—useful uselessness? Cell. Mol. Life Sci. 69, 3027–3036 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bond, C.S. & Fox, A.H. Paraspeckles: nuclear bodies built on long noncoding RNA. J. Cell Biol. 186, 637–644 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chen, L.L., DeCerbo, J.N. & Carmichael, G.G. Alu element-mediated gene silencing. EMBO J. 27, 1694–1705 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Prasanth, K.V. et al. Regulating gene expression through RNA nuclear retention. Cell 123, 249–263 (2005).

    Article  CAS  PubMed  Google Scholar 

  16. Zhang, Z. & Carmichael, G.G. The fate of dsRNA in the nucleus: a p54nrb-containing complex mediates the nuclear retention of promiscuously A-to-I edited RNAs. Cell 106, 465–475 (2001).

    Article  CAS  PubMed  Google Scholar 

  17. Brown, S.A. et al. PERIOD1-associated proteins modulate the negative limb of the mammalian circadian oscillator. Science 308, 693–696 (2005).

    Article  CAS  PubMed  Google Scholar 

  18. Duong, H.A., Robles, M.S., Knutti, D. & Weitz, C.J. A molecular mechanism for circadian clock negative feedback. Science 332, 1436–1439 (2011).

    Article  CAS  PubMed  Google Scholar 

  19. Kowalska, E. et al. NONO couples the circadian clock to the cell cycle. Proc. Natl. Acad. Sci. USA 110, 1592–1599 (2013).

    Article  CAS  PubMed  Google Scholar 

  20. Kowalska, E. et al. Distinct roles of DBHS family members in the circadian transcriptional feedback loop. Mol. Cell. Biol. 32, 4585–4594 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367, 1921–1929 (2012).

    Article  CAS  PubMed  Google Scholar 

  22. Rauch, A. et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 380, 1674–1682 (2012).

    Article  CAS  PubMed  Google Scholar 

  23. Vissers, L.E., de Vries, B.B. & Veltman, J.A. Genomic microarrays in mental retardation: from copy number variation to gene, from research to diagnosis. J. Med. Genet. 47, 289–297 (2010).

    Article  CAS  PubMed  Google Scholar 

  24. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 519, 223–228 (2015).

  25. Tyagarajan, S.K. & Fritschy, J.M. Gephyrin: a master regulator of neuronal function? Nat. Rev. Neurosci. 15, 141–156 (2014).

    Article  CAS  PubMed  Google Scholar 

  26. Tyagarajan, S.K. et al. Regulation of GABAergic synapse formation and plasticity by GSK3β-dependent phosphorylation of gephyrin. Proc. Natl. Acad. Sci. USA 108, 379–384 (2011).

    Article  CAS  PubMed  Google Scholar 

  27. Panzanelli, P. et al. Distinct mechanisms regulate GABAA receptor and gephyrin clustering at perisomatic and axo-axonic synapses on CA1 pyramidal cells. J. Physiol. (Lond.) 589, 4959–4980 (2011).

    Article  CAS  Google Scholar 

  28. Jacob, T.C. et al. Gephyrin regulates the cell surface dynamics of synaptic GABAA receptors. J. Neurosci. 25, 10469–10478 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Mullen, S.A. et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. Neurology 81, 1507–1514 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Zhang, G., Neubert, T.A. & Jordan, B.A. RNA binding proteins accumulate at the postsynaptic density with synaptic activity. J. Neurosci. 32, 599–609 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ruby, N.F. et al. Hippocampal-dependent learning requires a functional circadian system. Proc. Natl. Acad. Sci. USA 105, 15593–15598 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Castner, S.A. et al. Reversal of ketamine-induced working memory impairments by the GABAAalpha2/3 agonist TPA023. Biol. Psychiatry 67, 998–1001 (2010).

    Article  CAS  PubMed  Google Scholar 

  33. Hofmann, M. et al. Assessment of the effects of NS11394 and L-838417, alpha2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behav. Pharmacol. 23, 790–801 (2012).

    Article  CAS  PubMed  Google Scholar 

  34. Hines, R.M. et al. Disrupting the clustering of GABAA receptor α2 subunits in the frontal cortex leads to reduced gamma-power and cognitive deficits. Proc. Natl. Acad. Sci. USA 110, 16628–16633 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lehner, M. et al. Differences in the density of GABA-A receptor alpha-2 subunits and gephyrin in brain structures of rats selected for low and high anxiety in basal and fear-stimulated conditions, in a model of contextual fear conditioning. Neurobiol. Learn. Mem. 94, 499–508 (2010).

    Article  CAS  PubMed  Google Scholar 

  36. Yang, B. et al. Sh3pxd2b mice are a model for craniofacial dysmorphology and otitis media. PLoS ONE 6, e22622 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Baltes, C., Radzwill, N., Bosshard, S., Marek, D. & Rudin, M. Micro MRI of the mouse brain using a novel 400 MHz cryogenic quadrature RF probe. NMR Biomed. 22, 834–842 (2009).

    Article  PubMed  Google Scholar 

  38. Mohajeri, M.H. et al. Intact spatial memory in mice with seizure-induced partial loss of hippocampal pyramidal neurons. Neurobiol. Dis. 12, 174–181 (2003).

    Article  PubMed  Google Scholar 

  39. Gallagher, M., Burwell, R. & Burchinal, M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav. Neurosci. 107, 618–626 (1993).

    Article  CAS  PubMed  Google Scholar 

  40. Whishaw, I.Q. Cholinergic receptor blockade in the rat impairs locale but not taxon strategies for place navigation in a swimming pool. Behav. Neurosci. 99, 979–1005 (1985).

    Article  CAS  PubMed  Google Scholar 

  41. Cros, J. et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33, 375–386 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Schmittgen, T.D. & Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108 (2008).

  43. Li, B. & Dewey, C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Buerli, T. et al. Efficient transfection of DNA or shRNA vectors into neurons using magnetofection. Nat. Protoc. 2, 3090–3101 (2007).

    Article  CAS  PubMed  Google Scholar 

  45. Lardi-Studler, B. et al. Vertebrate-specific sequences in the gephyrin E-domain regulate cytosolic aggregation and postsynaptic clustering. J. Cell Sci. 120, 1371–1382 (2007).

    Article  CAS  PubMed  Google Scholar 

  46. Kuwahara, S. et al. PSPC1, NONO, and SFPQ are expressed in mouse Sertoli cells and may function as coregulators of androgen receptor-mediated transcription. Biol. Reprod. 75, 352–359 (2006).

    Article  CAS  PubMed  Google Scholar 

  47. Fritschy, J.M. & Mohler, H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359, 154–194 (1995).

    Article  CAS  PubMed  Google Scholar 

  48. Brunig, I., Suter, A., Knuesel, I., Luscher, B. & Fritschy, J.M. GABAergic terminals are required for postsynaptic clustering of dystrophin but not of GABAA receptors and gephyrin. J. Neurosci. 22, 4805–4813 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Notter, T., Panzanelli, P., Pfister, S., Mircsof, D. & Fritschy, J.M. A protocol for concurrent high-quality immunohistochemical and biochemical analyses in adult mouse central nervous system. Eur. J. Neurosci. 39, 165–175 (2014).

    Article  PubMed  Google Scholar 

  50. Dunkley, P.R., Jarvie, P.E. & Robinson, P.J. A rapid Percoll gradient procedure for preparation of synaptosomes. Nat. Protoc. 3, 1718–1728 (2008).

    Article  CAS  PubMed  Google Scholar 

Download references


We are grateful to the patients and their family members for their participation in our study and to the Functional Genomics Center Zürich (FGCZ) for transcriptomic services. This program has received a state subsidy managed by the National Research Agency under the Investments for the Future program bearing the reference ANR-10-IAHU-01.This study was also supported by the Centre National de la Recherche Scientifique (CNRS), the Fondation pour la Recherche Médicale (DEQ20120323702) and the Ministère de la Recherche et de l'Enseignement Supérieur, as well as by the Swiss National Science Foundation, the Zurich Clinical Research Priority Program “Sleep and Health,” the Zurich Fonds zur Förderung des akademischen Nachwuchses and the Zurich Neurozentrum (ZNZ). D.M., S.A.B. and S.K.T. are affiliates of the ZNZ Life Sciences Zurich graduate program, and S.A.B. is a member of the Zürich Center for Interdisciplinary Sleep Research (ZIS). The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003), a parallel funding partnership between the Wellcome Trust and the UK Department of Health, and the Wellcome Trust Sanger Institute (grant number WT098051). The views expressed in this publication are those of the author(s) and not necessarily those of the Wellcome Trust or the Department of Health. The research team acknowledges the support of the UK National Institute for Health Research, through the Comprehensive Clinical Research Network.

Author information

Authors and Affiliations




L.C., S.A.B., J.-M.F. and S.K.T. designed the study. J.A., M. Rio and K.P. recruited and evaluated the study subjects. N.B. performed and analyzed the human brain imaging, and D.M., P.S., A.S. and M. Rudin performed and analyzed the mouse brain imaging. M.L. analyzed whole-exome sequencing data and performed transcriptional analysis and western blot analysis on patient cells, and L.G. performed circadian analyses on patient cells. S.M. contributed to whole-exome sequencing data analysis. C.B.-F. performed whole-exome sequencing. N.C. and P.N. performed the bioinformatics studies. R.H. and S.J.M. supplied engineered virus for in vivo rescue experiments. D.M. executed and analyzed all experiments on mouse tissues, and D.M. and M.Ž. executed and analyzed experiments in rodent cells. D.M., C.K., F.C., A.-K.F. and D.P.W. performed and analyzed mouse behavioral experiments. A.M. contributed to the clinical evaluation of the patients. K.S.-P. and O.A. contributed to the WES analysis. G.B. prepared cultured neurons for all experiments in this study. All authors contributed to writing and editing the manuscript.

Corresponding authors

Correspondence to Steven A Brown, Shiva K Tyagarajan or Laurence Colleaux.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Additional information

A full list of consortium members appears in the Supplementary Note.

Integrated supplementary information

Supplementary Figure 1 Molecular analyses of patients MCCID1 and MCCID2

(a) Sanger sequencing chromatograms showing the NONO mutations in the probands and their parents. (b) Schematic representation of the NONO transcript showing exon structure. (c) Schematic overview of the NONO protein showing the different functional domains.

Supplementary Figure 2 Photographs of the two patients from the Necker Hospital study, and a third patient from the Deciphering Developmental Disorders cohort

Supplementary Figure 3 Full-length western blot of NONO

Western blot of NONO protein in patients and controls, using a different polyclonal antibody from the one used in Figure 1.

Supplementary Figure 4 Reduced circadian amplitude in patient fibroblasts.

(a) Graph of average circadian oscillations of bioluminescence from Bmal1-luciferase reporter-infected fibroblasts from patients (grey) or siblings (black). Y-axis, background-subtracted bioluminescence in photons per minute; X-axis, time in days. Depicted curve is the average of three independent experiments in technical quadruplicate. (b) Circadian period measured in cells from controls (black bars) and patients (open bars). (c) Circadian amplitude measured in the same cells (arbitrary units). Student t-test, p<0.001. Values for both panels are the average of three independent experiments with fibroblasts from both patients and their siblings in technical quadruplicate.

Source data

Supplementary Figure 5 Brain morphology in Nonogt mice.

(a) Photograph of representative brains from WT (left) and Nonogt (right) mice. (b) Quantification of weight of whole brain, cortex, and cerebellum. N=5-9 mice per genotype. Student t-test. White bars, WT. grey bars, Nonogt. In this and subsequent figures, ***p<0.001, **p<0.01, *p<0.05. Quantification of all brain parameters from different morphological tests is shown in detail in Table S4.

Source data

Supplementary Figure 6 Anxiety-related phenotypes in Nonogt mice.

(a) Percentage of time spent in open arms of elevated plus-maze. N=13-14 mice per genotype. Student t-test, p<0.001 (b) Post-conditioning startle response in prepulse inhibition test. Y-axis, whole-body startle response in volts; X-axis, stimulus in decibels. N=13-14 mice per genotype. Student t-test, p<0.01 or 0.001 as indicated. (c) Open-field exploration. Y-axis, percentage of area surface tiles visited. X-axis, subsequent 5-minute intervals after commencement of test. N=18 mice per genotype, repeated ANOVA, gene p<.0002, time p<.0001, time x gene n.s. (d) Light-dark transition test. Y-axis, percentage of time spent in zones indicated on X-axis. N=18 mice per genotype, repeated ANOVA, gene p<.0001, zone p<.0001, zone x gene p<0.0001. In all panels, Nonogt mice are represented by grey bars/circles, compared to WT littermates (open).

Source data

Supplementary Figure 7 Cell-type- and layer-specific localization of NONO in mouse brain.

(a) Staining of hippocampal cell nuclei by DAPI (blue), anti-NONO (green), and neuron-specific anti-NeuN or astrocyte-specific anti-GFAP (red, left or right column respectively). (b) Identical staining of cortex.

Supplementary Figure 8 Widespread dysregulation of transcription in Nonogt mouse hippocampi.

(a) Volcano plot of deregulated genes. Red dots, p<0.01 and log2>0.5. (b) Reduced GABRA2 mRNA levels in hippocampi of Nonogt mice. White bars, WT. grey bars, Nonogt. Student t-test, N=4. (c) List of most severely deregulated transcripts, showing upregulation of sister DBHS family members Sfpq and Pspc1.

Source data

Supplementary Figure 9 Overexpression of PSPC1 and SFPQ protein in Nonogt mouse hippocampi.

(a) Western blots of hippocampal protein extracts from widtype and Nonogt mice hippocampi, probed with anti-NONO, anti-PSPC1, anti-SFPQ, and anti-β-actin. N=3 mice per genotype. (b) Quantification of (a). White bars, WT. Black bars, Nonogt. Student t-test, p<0.01.

Source data

Supplementary Figure 10 Transcript abundance in different neuronal compartments in Nonogt mice.

(a) Profile of the mouse forebrain synaptic transcriptome. Y-axis, ratio of transcript reads from synaptome RNA sequencing compared to total. Selected transcripts previously characterized to be transported to synapses (Kif5a, Shank3, CamK2A, Arc, Gabra2), present throughout the cell (Map2, Actb), or retained in the nucleus (Neat1) are indicated to demonstrate the quality of synaptosomal transcript enrichment. Blue shading, transcripts more than 1.5x enriched. (b) Quantification of Neat1 compared to Gapdh in whole-cell homogenate, purified nuclei, supernatant, or gradient-purified synaptosomes from WT (white bars) or Nonogt mice (solid bars). (c) Quantification of CamkII compared to Gapdh. (d) Quantification of Gabra2 compared to Gapdh.

Source data

Supplementary Figure 11 Reduction of synaptic GABRA2 in Nonogt mice.

(a) Western blot showing fractionation of mouse forebrain into different neuronal compartments by density gradient centrifugation. Immunohistochemistry using antibodies against NONO, gephyrin, and GABA is pictured. As a control, β-actin and dendrite-enriched PSD-95 are also shown. (b) Quantification of the reduction in GABRA2 levels in each compartment.

Source data

Supplementary Figure 12 Specific reduction of Gabra2 transcript levels in cultured Nonogt neurons.

(a) Single-transcript-resolution RNA in-situ hybridization to detect abundance of collybistin (CB, blue), Gabra1 (blue), Gabra2 (red), and CamKII (red) in WT or Nonogt neurons. Two transcripts were tested in different colors in a single plate of cells, and depicted in a single column. (b) Quantification of collybistin transcript distribution in puncta number per cell for 44-56 cells from 2 experiments. (C) Similar quantification of Gabra2. Solid circles, Nonogt neurons; open circles, WT.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–12, Supplementary Tables 1–7 and Supplementary Note (PDF 3997 kb)

Supplementary Methods Checklist (PDF 422 kb)

Source data

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mircsof, D., Langouët, M., Rio, M. et al. Mutations in NONO lead to syndromic intellectual disability and inhibitory synaptic defects. Nat Neurosci 18, 1731–1736 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing